Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Technology Industry News Can Accelerant’s $724m ARX IPO make its risk exchange a benchmark for insurtech growth in 2025? Accelerant’s $724M ARX IPO shows insurtech’s comeback. Learn how its risk exchange and growth plans could reshape specialty insurance. byPallavi MadhirajuJuly 24, 2025